The association of disease stage, age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), smoking status, tumor histology, neutrophil-to-lymphocyte ratio (NLR) and albumin levels prior durvalumab initiation, PD-L1 expression levels, and number of days between CRT end and durvalumab initiation with PFS and OS was assessed in univariable analyses (Fig. 1). This evidence concerns the gene ALB and neoplasm.